![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Intelligent Ultrasound Group Plc | IUG | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
12.875 | 12.875 | 12.875 | 12.875 | 12.875 |
Industry Sector |
---|
HEALTH CARE EQUIPMENT & SERVICES |
Top Posts |
---|
Posted at 22/1/2025 17:43 by gsbmba99 Just for the fun of it, I checked the FDA's 510(k) database. As it happens, a new version of Voluson Expert was approved in late December. The filing date was 24 July or 6 days after the proposed sale of the AI business was announced. This new 510(k) features a new SonoLyst product - 1st Trimester - in addition to 2nd Trimester. I wonder if I am reading too much into the fact that the filing wasn't made until after IUG agreed to sell them the Clinical AI business? |
Posted at 19/12/2024 10:05 by 40 fathoms @route1 - This offers supersedes the "Capital Return". It states in the RNS any dividend paid going forward will reduce the offer price. So 13.4p is the full amount that will be received. |
Posted at 12/12/2024 13:37 by bmcollins I was hoping for some hard news by now, at this rate our IUG Christmas present could be a Hogmany one or even later than that ! |
Posted at 27/11/2024 07:10 by bamboo2 Capital return updateIntelligent Ultrasound Group plc (AIM: IUG), the ultrasound simulation and education company, announces that the Company has completed all the necessary administrative steps (including court approval) for the reduction of capital. This is now subject to registration at Companies House before it becomes effective after which the Company will issue a further announcement confirming registration. Once effective, the Group will have the distributable reserves required to make a material return of capital to shareholders. The Group therefore expects to confirm the plans for its Simulation Business and the exact amount of money to be returned during December 2024. In an update on the current year's trading the Group confirms that, as at 22 November, Group unaudited revenue was £8.1m (same period in 2023: £9.2m), with £7.4m (same period in 2023: £8.4m) from continuing operations and £0.7m (same period in 2023: £0.8m) from discontinued operations. Cash at bank was £39.6m. |
Posted at 01/10/2024 12:11 by bamboo2 1 October 2024Intelligent Ultrasound Group plc (the "Group" or the "Company") Completion of sale of Clinical AI Business Further to the announcement on 18th July 2024, Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound AI software and simulation company, is pleased to announce it has completed the sale of its Clinical AI Business (Intelligent Ultrasound Limited and certain other clinical AI related assets) to GE HealthCare for an enterprise value of £40.5 million on a cash free/debt free basis. |
Posted at 27/9/2024 08:53 by jane deer Section 2 of the circular (page 7) clarifies that the return could be a dividend or the return of capital through the purchase of own shares.There is a tax section in the circular (section 3) but it clearly has not been properly proof-read. It just includes the disclaimer about not relying on it for tax advice, without any actual comments on the tax situation for UK shareholders. |
Posted at 27/9/2024 08:08 by bmcollins Presumably our anticipated distribution will be treated as a dividend for tax purposes thus attracting income tax unless held inside a tax free wrapper, ISA/SIPP etc ? |
Posted at 27/9/2024 06:27 by bamboo2 27 September 2024Intelligent Ultrasound Group plc (the "Group" or the "Company") Reduction of Capital: Posting of Circular & Notice of General Meeting Further to the conditional sale of the Clinical AI Business to GE HealthCare for £40.5 million expected to complete on 1st October, Intelligent Ultrasound Group plc (AIM: IUG), announces that it is proposing to undertake a reduction of capital as the preliminary step to provide the distributable reserves required to return capital to shareholders. The reduction of capital will be subject to shareholder approval and a court approval process. The Company has today posted a Circular to shareholders, including on our website, setting out the reasons for the capital reduction, and including a notice of the General Meeting to approve the resolution, which will be held on 15th October at the Company offices in Cardiff. The capital reduction is expected to be confirmed by Court Order on 18th November after which further details on the Company's plans will also be announced. EXPECTED TIMETABLE OF PRINCIPAL EVENTS [2024] Publication of this Document 27 September Latest time and date for receipt of Forms of Proxy for the GM 11 October General Meeting 15 October Court directions hearing 4 November Court hearing to confirm Capital Reduction 18 November Registration of Court Order and Effective Date Expected to take place 2 business days after the Court hearing to confirm Capital Reduction |
Posted at 15/8/2024 08:05 by route1 As a shareholder I have been out of touch lately.Has IUG declared a dividend, if so how much will it be per share, and what is the payment date?Grateful for any information. |
Posted at 22/7/2024 12:44 by bamboo2 Hi 40F and bmc, thank you for your thoughts.GEHC had flagged up a supply backlog, which led to reduction in Ultrasound deliveries on their Q1 update. They have some very long lead times for certain machines, and this won't have helped our sales. It's a shame that the two co's could not find a way to agree on new terms, however this sale does remove much of the reliance and focus on a single customer. I would have preferred GEHC to take the whole co really, and this was my hope when first getting involved back in late 2022 and early 2023. With regard to other possibilities, TRX is at a similar point in maturity to IUG as they move into profit. I also like FNX. Parent and co-owner of IUG, IPGroup [IPO] is at all time lows, and may be worth a look, although management come across as weak. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions